Moving the Needle Forward in Cancer Rehabilitation

Commentary
Video

It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.

When looking towards the future, Jessica Cheng, MD, hopes that patients and clinicians will underscore the importance of adding cancer rehabilitation into treatment plans as the field becomes more widespread.

She noted that with the implementation of cancer rehabilitation into treatment strategies, performance status and function can be significantly improved, which may correlate with better outcomes and reduced hospital stays. Cheng, assistant clinical professor in the Department of Supportive Care Medicine at City of Hope, wants the word to spread about this niche area, as it may allow for more informed treatment decisions and serve as an “integral part of the cancer space”.

With her catchphrase of “prehab for all”, she hopes that colleagues will learn more about cancer rehabilitation and what it can mean for their patients. By developing a greater understanding of cancer rehabilitation, practices may help patients navigate their treatment course more easily while aiding their recovery following therapy.


Transcript:

I see the value of rehabilitation medicine in the cancer space as an integral part of the cancer space. My heart’s desire is that every institution that takes care of patients with cancer will recognize the importance of optimizing function and performance status from the beginning and throughout the cancer journey from prehabilitation to rehabilitation. There’s a lot of room for growth there.

My catchphrase recently is “prehab for all”. I want everyone to be armed with this knowledge of what they can do that’s in their control to optimize their abilities for meaningful activities throughout the cancer journey. I hope that oncologists and rehabilitation physicians alike will see that there’s an opportunity with cancer prehabilitation to enable [patients] to get their cancer treatment, get through it better, and recover better. That’s my hope: that this will just spread even more like wildfire than it already is.

Recent Videos
Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
Surbhi Sidana, MD, spoke about multiple myeloma developments with the potential to impact clinical practice, particularly early line use of bispecific antibodies.
Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma.
Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.
Surbhi Sidana, MD, discussed outpatient supportive care for patients following immunotherapy treatment for hematologic cancers.
Related Content